HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CBBB head

This article was originally published in The Rose Sheet

Executive Summary

Newly appointed Council for Better Business Bureaus President and CEO Steven Cole identifies four challenges for his agency going forward - "strategic planning, consistent branding, building a world class information technology system and the internalization of the Better Business Bureaus." Speaking during a presentation at the National Advertising Division annual conference in New York City Sept. 26-27, Cole says he was selected in part because of the importance the board attributes to self-regulation. "I'm the first person selected from within the organization and that is not an accident," he states, adding, "I know the subject matter, I know the importance of self-regulation, I understand why we simply must be an effective alternative to the courts, [and] I appreciate our need to be competent, transparent, impartial and credible." Cole's appointment is effective Oct. 1 and was announced Aug. 17 (1"The Rose Sheet" Aug. 29, 2005, In Brief)...

You may also be interested in...


Steven Cole is appointed president and CEO, effective in October, the Council of Better Business Bureaus announces Aug. 17. Cole has been with CBBB since 1987, most recently serving as VP-general counsel and corporate secretary. Cole is credited with playing "a major role in the BBB's initiative to encourage consumer trust and confidence in the online marketplace" and with steering international activities, CBBB says. Cole will succeed Kenneth Hunter, who is departing to head a philanthropic business venture...

Sanofi Bets Big On IO With Synthorx Buy

The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.

Global Industry Hails Bioequivalence Progress

For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts